The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study
Open accessAbstract
ASTERIA I was a 40-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous omalizumab as add-on therapy for 24 weeks in patients with chronic idiopathic urticaria/spontaneous urticaria (CIU/CSU) who remained symptomatic despite H1 antihistamine treatment at licensed doses. Patients aged 12-75 years with CIU/CSU who remained symptomatic despite treatment with approved doses of H1 antihistamines were randomized (1:1:1:1) in a double-blind manner to subcutaneous omalizumab 75 mg, 150 mg, or 300 mg or placebo every 4 weeks for 24 weeks followed by 16 weeks of follow-up. The primary end point was change from baseline in weekly itch severity score (ISS) at week 12. Among randomized patients (N=319: placebo n=80, omalizumab 75 mg n=78, 150 mg n=80, 300 mg n=81), 262 (82.1%) completed the study. Compared with placebo (n=80), mean weekly ISS was reduced from baseline to week 12 by an additional 2.96 points (95% confidence interval (CI): -4.71 to -1.21; P=0.0010), 2.95 points (95% CI: -4.72 to -1.18; P=0.0012), and 5.80 points (95% CI: -7.49 to -4.10; P<0.0001) in the omalizumab 75-mg (n=77), 150-mg (n=80), and 300-mg groups (n=81), respectively. The omalizumab 300-mg group met all nine secondary end points, including a significant decrease in the duration of time to reach minimally important difference response (⩾5-point decrease) in weekly ISS (P<0.0001) and higher percentages of patients with well-controlled symptoms (urticaria activity score over 7 days (UAS7) ⩽6: 51.9% vs. 11.3%; P<0.0001) and complete response (UAS7=0: 35.8% vs. 8.8%; P<0.0001) versus placebo. During the 24-week treatment period, 2 (2.9%), 3 (3.4%), 0, and 4 (5.0%) patients in the omalizumab 75-mg, 150-mg, 300-mg, and placebo groups, respectively, experienced a serious adverse event. Omalizumab 300 mg administered subcutaneously every 4 weeks reduced weekly ISS and other symptom scores versus placebo in CIU/CSU patients who remained symptomatic despite treatment with approved doses of H1 antihistamines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Maurer, M., Rosén, K., Hsieh, H.-J., Saini, S., Grattan, C., Gimenéz-Arnau, A., Agarwal, S., Doyle, R., Canvin, J., Kaplan, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215372 · Cited by 1,105
Self-citationEAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria
Zuberbier, T., Asero, R., Bindslev‐Jensen, C., Walter Canonica, G., Church, M. K., Giménez‐Arnau, A., Grattan, C. E. H., Kapp, A., Merk, H. F., Rogala, B., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02179.x · Cited by 731
Self-citationKaplan, A., Ledford, D., Ashby, M., Canvin, J., Zazzali, J. L., Conner, E., Veith, J., Kamath, N., Staubach, P., Jakob, T., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.05.013 · Cited by 573
Self-citationEAACI/GA²LEN/EDF/WAO guideline: management of urticaria
Zuberbier, T., Asero, R., Bindslev‐Jensen, C., Walter Canonica, G., Church, M. K., Giménez‐Arnau, A. M., Grattan, C. E. H., Kapp, A., Maurer, M., Merk, H. F., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02178.x · Cited by 527
Self-citationEAACI/GA2LEN/EDF guideline: management of urticaria
Zuberbier, T., Bindslev‐Jensen, C., Canonica, W., Grattan, C. E. H., Greaves, M. W., Henz, B. M., Kapp, A., Kozel, M. M. A., Maurer, M., Merk, H. F., et al. (2006) · Allergy · doi:10.1111/j.1398-9995.2005.00962.x · Cited by 461
Self-citationOmalizumab-induced reductions in mast cell FcεRI expression and function
Beck, L. A., Marcotte, G. V., MacGlashan, D., Togias, A., & Saini, S. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.06.032 · Cited by 456
Self-citationSaini, S., Rosen, K. E., Hsieh, H.-J., Wong, D. A., Conner, E., Kaplan, A., Spector, S., & Maurer, M. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.06.010 · Cited by 398
Self-citationMaurer, M., Altrichter, S., Bieber, T., Biedermann, T., Bräutigam, M., Seyfried, S., Brehler, R., Grabbe, J., Hunzelmann, N., Jakob, T., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.04.038 · Cited by 360
Self-citationStaevska, M., Popov, T. A., Kralimarkova, T., Lazarova, C., Kraeva, S., Popova, D., Church, D. S., Dimitrov, V., & Church, M. K. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.047 · Cited by 327
Treatment of chronic autoimmune urticaria with omalizumab
Kaplan, A. P., Joseph, K., Maykut, R. J., Geba, G. P., & Zeldin, R. K. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.07.006 · Cited by 286
New concepts in chronic urticaria
Vonakis, B. M., & Saini, S. S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.09.005 · Cited by 117
Self-citationOng, Y. E., Menzies-Gow, A. N., Barkans, J. R., Benyahia, F., Ou, T.-T., Sun, Y., & Kay, A. B. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.05.035 · Cited by 97
Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria
Maurer, M., Magerl, M. A. K., Metz, M., & Zuberbier, T. (2013) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.12194 · Cited by 72
Self-citationDevelopment of a daily diary for patients with chronic idiopathic urticaria
Mathias, S. D., Dreskin, S. C., Kaplan, A. P., Saini, S. S., Spector, S. L., & Rosén, K. E. (2010) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2010.06.011 · Cited by 69
Self-citationHow IgE upregulates the allergic response
Saini, S. S., & MacGlashan, D. W. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00404-1 · Cited by 54
Self-citationSafety of omalizumab in asthma
Tan, R. A., & Corren, J. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.563840 · Cited by 35
Cited by
Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A. H., Baker, D., Ballmer‐Weber, B., Bernstein, J. A., Bindslev‐Jensen, C., Brzoza, Z., Buense Bedrikow, R., et al. (2018) · Allergy · doi:10.1111/all.13397 · Cited by 1,445
Self-citationZuberbier, T., Abdul Latiff, A. H., Abuzakouk, M., Aquilina, S., Asero, R., Baker, D., Ballmer‐Weber, B., Bangert, C., Ben‐Shoshan, M., Bernstein, J. A., et al. (2022) · Allergy · doi:10.1111/all.15090 · Cited by 1,263
Self-citationTargeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766
European S2k Guideline on Chronic Pruritus
Weisshaar, E., Szepietowski, J., Dalgard, F., Garcovich, S., Gieler, U., Giménez-Arnau, A., Lambert, J., Leslie, T., Mettang, T., Misery, L., et al. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3164 · Cited by 405
Kolkhir, P., Giménez-Arnau, A. M., Kulthanan, K., Peter, J., Metz, M., & Maurer, M. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00389-z · Cited by 382
Self-citation
Metadata
- Authors
- Saini, S. S., Bindslev-Jensen, C., Maurer, M., Grob, J.-J., Bülbül Baskan, E., Bradley, M. S., Canvin, J., Rahmaoui, A., Georgiou, P., Alpan, O., Spector, S., & Rosén, K.
- Venue
- Journal of Investigative Dermatology
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 135
- Issue
- 1
- Pages
- 67-75
- ISSN
- 0022-202X (ISSN-L)
- OpenAlex
- W1968667225
- Cited by
- 471
- References
- 18
- FWCI
- 33.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.